$4803 | SAVE $847 | Single User
$5653 | SAVE $997 | Multi User
$6928 | SAVE $1,222 | Corporate License
$8500 | SAVE $1,500 | Enterprise License

Artificial Intelligence (AI) in Drug Discovery Market by Component (Software, Service), Technology (ML, DL), Application (Neurodegenerative Diseases, Immuno-Oncology, CVD), End User (Pharmaceutical & Biotechnology, CRO), Region - Global forecast to 2024
[Published by MarketsandMarkets]

Published by MarketsandMarkets: 19 Nov 2019 | 237298 | In Stock

Introduction

“Growing number of cross-industry collaborations and partnerships and the need to control drug discovery & development costs and reduce the overall time taken in this process are the key factors driving the AI in the drug discovery market.”

The global AI in the drug discovery market is projected to reach USD 1,434 million by 2024 from USD 259 million in 2019, at a CAGR of 40.8% during the forecast period. Growth in this market is mainly driven by growing number of cross-industry collaborations and partnerships, the need to control drug discovery & development costs and reduce the overall time taken in this process, the rising adoption of cloud-based applications & services, and the impending patent expiry of blockbuster drugs. On the other hand, a lack of data sets in the field of drug discovery and the inadequate availability of skilled labor are some of the factors challenging the growth of the market.

“The immuno-oncology segment accounted for the largest share in 2019.”

Based on application, the artificial intelligence in the drug discovery market is segmented into neurodegenerative diseases, immuno-oncology, cardiovascular disease, metabolic diseases, and other applications. The immuno-oncology segment accounted for the largest share of 44.6% of the AI in the drug discovery market in 2018, owing to the increasing demand for effective cancer drugs. Neurodegenerative diseases form the fastest-growing application segment, with a CAGR of 42.9% during the forecast period. The ability of AI to discover drugs for complex diseases and the emphasis of market players on providing AI-based platforms for neurological diseases are responsible for the fast growth of this application segment.

“The Research centers and academic & government institutes segment to register the highest growth rate in the forecast period.”

Based on end-user, the AI in the drug discovery market is segmented into pharmaceutical & biotechnology companies, contract research organizations, and research centers and academic, & government institutes. In 2018, the pharmaceutical & biotechnology companies segment accounted for the largest share in the AI in the drug discovery market. AI and machine learning to allow pharmaceutical companies to operate more efficiently and substantially improve success rates at the early stages of drug development. This is one of the major factors driving the growth of this market. Research centers and academic & government institutes are expected to show the highest growth of 43.6%.during the forecast period. The growth of the CROs segment is tied to that of pharmaceutical & biotechnology companies, as the rise in research and production activity will ensure sustained demand for contract services.

“North America to be the largest and the fastest-growing regional market.”

North America, which comprises the US, Canada, and Mexico, forms the largest market for AI in drug discovery. These countries have been early adopters of AI technology in drug discovery and development. In the North American market, the US is a significant contributor. Also, prominent AI technology providers, such as IBM, Google, Microsoft, NVIDIA, and Intel, are headquartered in the US; their strong presence is a key contributor to market growth. Other drivers include the well-established pharmaceutical industry, high focus on R&D & substantial investment, and the presence of globally leading pharmaceutical companies. These are some of the major factors responsible for the large share and high growth rate of this market.

The primary interviews conducted for this report can be categorized as follows:

• By Company Type: Tier 1 (28%), Tier 2 (42%), and Tier 3 (30%)

• By Designation: C-level (30%), D-level (34%), and Others (36%)

• By Region: North America (46%), Europe (25%), Asia (18%), and the RoW (11%)

List of Companies Profiled in the Report

• IBM Corporation (US)

• Microsoft (US), Google (US)

• NVIDIA Corporation (US)

• Atomwise, Inc. (US)

• Deep Genomics (Canada)

• Cloud Pharmaceuticals (US)

• Insilico Medicine (US)

• Benevolent AI (UK)

• Exscientia (UK)

• Cyclica (Canada)

• BIOAGE (US)

• Numerate (US)

• Numedii (US)

• Envisagenics (US)

• twoXAR (US)

• OWKIN, Inc. (US)

• XtalPi (US)

• Verge Genomics (US)

• Berg LLC (US)

Research Coverage:

This report provides a study of the AI in the drug discovery market. It aims at estimating the size and future growth potential of the market across different segments, such as offering, technology, application, end-user, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of revenue numbers for the overall AI in drug discovery market and its subsegments. This report will also help stakeholders understand the competitive landscape, and gain insights to better position their business and make suitable go-to-market strategies. It will also enable stakeholders to understand the pulse of the market and provide them with information on the key market drivers, challenges, and opportunities.

Table of Contents
for Artificial Intelligence (AI) in Drug Discovery Market by Component (Software, Service), Technology (ML, DL), Application (Neurodegenerative Diseases, Immuno-Oncology, CVD), End User (Pharmaceutical & Biotechnology, CRO), Region - Global forecast to 2024 [Published by MarketsandMarkets]

  • TABLE OF CONTENTS

    1 INTRODUCTION 17

    1.1 OBJECTIVES OF THE STUDY 17

    1.2 MARKET DEFINITION 17

    1.3 MARKET SCOPE 18

    1.3.1 MARKETS COVERED 18

    1.3.2 YEARS CONSIDERED FOR THE STUDY 19

    1.4 CURRENCY 19

    1.5 LIMITATIONS 19

    1.6 STAKEHOLDERS 20

    2 RESEARCH METHODOLOGY 21

    2.1 RESEARCH DATA 21

    2.1.1 SECONDARY SOURCES 22

    2.1.1.1 Key data from secondary sources 23

    2.1.2 PRIMARY SOURCES 23

    2.1.2.1 Key data from primary sources 24

    2.1.2.2 Key industry insights 25

    2.2 MARKET SIZE ESTIMATION 26

    2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 28

    2.4 ASSUMPTIONS FOR THE STUDY 29

    3 EXECUTIVE SUMMARY 30

    4 PREMIUM INSIGHTS 35

    4.1 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET OVERVIEW 35

    4.2 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING (2019–2024) 36

    4.3 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE & REGION (2018) 37

    4.4 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 38

    5 MARKET OVERVIEW 39

    5.1 INTRODUCTION 39

    5.2 MARKET DYNAMICS 39

    5.2.1 MARKET DRIVERS 40

    5.2.1.1 Growing number of cross-industry collaborations and partnerships 40

    5.2.1.2 Need to control drug discovery & development costs and reduce time 41

    5.2.1.3 Patent expiry 41

    5.2.2 MARKET OPPORTUNITIES 42

    5.2.2.1 Growing biotechnology industry 42

    5.2.2.2 Emerging markets 42

    5.2.3 MARKET CHALLENGES 42

    5.2.3.1 Limited availability of data sets 42

    6 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING 43

    6.1 INTRODUCTION 44

    6.2 SOFTWARE 44

    6.2.1 BENEFITS OFFERED BY SOFTWARE IN DRUG DISCOVERY & STRONG DEMAND AMONG END USERS ARE DRIVING MARKET GROWTH 44

    6.3 SERVICES 46

    6.3.1 SERVICES SEGMENT TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD 46

    7 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY 48

    7.1 INTRODUCTION 49

    7.2 MACHINE LEARNING 49

    7.2.1 INCREASING ADOPTION OF ML BY RESEARCH CENTERS & PHARMACEUTICAL COMPANIES TO SUPPORT THE GROWTH OF THIS SEGMENT 49

    7.2.2 DEEP LEARNING 51

    7.2.3 SUPERVISED LEARNING 54

    7.2.4 REINFORCEMENT LEARNING 56

    7.2.5 UNSUPERVISED LEARNING 57

    7.2.6 OTHER MACHINE LEARNING TECHNOLOGIES 59

    7.3 OTHER TECHNOLOGIES 61

    8 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION 63

    8.1 INTRODUCTION 64

    8.2 IMMUNO-ONCOLOGY 64

    8.2.1 HIGH PREVALENCE OF CANCER AND SHORTAGE IN THE SUPPLY OF CANCER DRUGS ARE THE KEY FACTORS DRIVING MARKET GROWTH 64

    8.3 NEURODEGENERATIVE DISEASES 66

    8.3.1 AI IS BEING USED TO RESOLVE EXISTING CHALLENGES IN NEUROLOGICAL DISEASE DRUG DEVELOPMENT 66

    8.4 CARDIOVASCULAR DISEASES 68

    8.4.1 RISING DEMAND FOR CVD DRUGS IS DRIVING MARKET GROWTH 68

    8.5 METABOLIC DISEASES 70

    8.5.1 ROLE OF AI IN UNCOVERING SMALL-MOLECULE THERAPIES IS DRIVING ITS ADOPTION IN THIS SEGMENT 70

    8.6 OTHER APPLICATIONS 72

    9 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER 74

    9.1 INTRODUCTION 75

    9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 75

    9.2.1 RISING DEMAND FOR SOLUTIONS TO CUT TIME AND COSTS OF DRUG DEVELOPMENT HAVE DRAWN END-USER ATTENTION TO AI 75

    9.3 CONTRACT RESEARCH ORGANIZATIONS 78

    9.3.1 GROWING TREND OF OUTSOURCING PROVIDES SIGNIFICANT OPPORTUNITIES FOR CROS 78

    9.4 RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES 80

    9.4.1 THIS SEGMENT IS EXPECTED TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD 80

    10 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY REGION 82

    10.1 INTRODUCTION 83

    10.2 NORTH AMERICA 83

    10.2.1.1 US 86

    10.2.1.1.1 Strong economy and trend of early adoption of technologies are driving market growth in the US 86

    10.2.1.2 Canada 89

    10.2.1.2.1 Growing research on AI technologies and emergence of new AI-based start-ups will support the market in Canada 89

    10.2.1.3 Mexico 91

    10.2.1.3.1 Government initiatives will support market growth in Mexico 91

    10.3 EUROPE 92

    10.3.1 UK 95

    10.3.1.1 The UK holds the largest share of the European market 95

    10.3.2 GERMANY 98

    10.3.2.1 Government support and favorable training programs are major market drivers in Germany 98

    10.3.3 FRANCE 99

    10.3.3.1 Strong government support and favorable strategies & initiatives form key drivers of the market in France 99

    10.3.4 REST OF EUROPE 101

    10.4 ASIA PACIFIC 103

    10.4.1 JAPAN 105

    10.4.1.1 Japan dominates the APAC market for AI in drug discovery 105

    10.4.2 CHINA 106

    10.4.2.1 Growing CMOs market and cross-industry collaborations are factors responsible for the growth of the market in China 106

    10.4.3 INDIA 108

    10.4.3.1 Steady adoption of AI technologies will drive market growth in India 108

    10.4.4 REST OF ASIA PACIFIC 110

    10.5 REST OF THE WORLD 112

    11 COMPETITIVE LANDSCAPE 114

    11.1 OVERVIEW 114

    11.2 MARKET SHARE ANALYSIS 116

    11.3 COMPETITIVE LEADERSHIP MAPPING 117

    11.3.1 VISIONARY LEADERS 117

    11.3.2 DYNAMIC DIFFERENTIATORS 117

    11.3.3 INNOVATORS 117

    11.3.4 EMERGING COMPANIES 117

    11.4 COMPETITIVE SITUATION AND TRENDS 119

    11.4.1 PRODUCT LAUNCHES AND ENHANCEMENTS 119

    11.4.2 EXPANSIONS 119

    11.4.3 ACQUISITIONS 120

    11.4.4 OTHER STRATEGIES 120

    12 COMPANY PROFILES 121

    (Business Overview, Products Offered, Recent Developments, MnM View)*

    12.1 MICROSOFT CORPORATION 121

    12.2 NVIDIA CORPORATION 123

    12.3 IBM CORPORATION 125

    12.4 GOOGLE (A SUBSIDIARY OF ALPHABET INC.) 127

    12.5 ATOMWISE, INC. 130

    12.6 DEEP GENOMICS 132

    12.7 CLOUD PHARMACEUTICALS, INC. 133

    12.8 INSILICO MEDICINE 134

    12.9 BENEVOLENTAI 135

    12.10 EXSCIENTIA 136

    12.11 CYCLICA 138

    12.12 BIOAGE 140

    12.13 NUMERATE 141

    12.14 NUMEDII, INC. 142

    12.15 ENVISAGENICS 143

    12.16 TWOXAR, INCORPORATED 144

    12.17 OWKIN, INC. 145

    12.18 XTALPI, INC. 146

    12.19 VERGE GENOMICS 147

    12.20 BERG LLC 148

    *Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies.

    13 APPENDIX 149

    13.1 DISCUSSION GUIDE 149

    13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 152

    13.3 AVAILABLE CUSTOMIZATIONS 154

    13.4 RELATED REPORTS 154

    13.5 AUTHOR DETAILS 155

List Of Tables
in Artificial Intelligence (AI) in Drug Discovery Market by Component (Software, Service), Technology (ML, DL), Application (Neurodegenerative Diseases, Immuno-Oncology, CVD), End User (Pharmaceutical & Biotechnology, CRO), Region - Global forecast to 2024 [Published by MarketsandMarkets]

LIST OF TABLES


TABLE 1 INDICATIVE LIST OF COLLABORATIONS AND PARTNERSHIPS (2017–2019) 40

TABLE 2 INDICATIVE LIST OF DRUGS LOSING PATENT IN 2019 41

TABLE 3 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING,

2017–2024 (USD MILLION) 44

TABLE 4 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SOFTWARE,

BY REGION, 2017–2024 (USD MILLION) 45

TABLE 5 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SOFTWARE, BY COUNTRY, 2017–2024 (USD MILLION) 45

TABLE 6 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SOFTWARE, BY COUNTRY, 2017–2024 (USD MILLION) 45

TABLE 7 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SOFTWARE, BY COUNTRY, 2017–2024 (USD MILLION) 46

TABLE 8 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SERVICES,

BY REGION, 2017–2024 (USD MILLION) 46

TABLE 9 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SERVICES, BY COUNTRY, 2017–2024 (USD MILLION) 47

TABLE 10 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SERVICES, BY COUNTRY, 2017–2024 (USD MILLION) 47

TABLE 11 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SERVICES,

BY COUNTRY, 2017–2024 (USD MILLION) 47

TABLE 12 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY,

2017–2024 (USD MILLION) 49

TABLE 13 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2017–2024 (USD MILLION) 50

TABLE 14 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY REGION, 2017–2024 (USD MILLION) 50

TABLE 15 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY COUNTRY, 2017–2024 (USD MILLION) 50

TABLE 16 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY COUNTRY, 2017–2024 (USD MILLION) 51

TABLE 17 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY COUNTRY, 2017–2024 (USD MILLION) 51

TABLE 18 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DEEP LEARNING,

BY REGION, 2017–2024 (USD MILLION) 52

TABLE 19 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DEEP LEARNING, BY COUNTRY, 2017–2024 (USD MILLION) 52

TABLE 20 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DEEP LEARNING, BY COUNTRY, 2017–2024 (USD MILLION) 53

TABLE 21 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DEEP LEARNING, BY COUNTRY, 2017–2024 (USD MILLION) 53

TABLE 22 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SUPERVISED LEARNING, BY REGION, 2017–2024 (USD MILLION) 54

TABLE 23 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET

FOR SUPERVISED LEARNING, BY COUNTRY, 2017–2024 (USD MILLION) 54

TABLE 24 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SUPERVISED LEARNING, BY COUNTRY, 2017–2024 (USD MILLION) 55

TABLE 25 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SUPERVISED LEARNING, BY COUNTRY, 2017–2024 (USD MILLION) 55

TABLE 26 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR REINFORCEMENT LEARNING, BY REGION, 2017–2024 (USD MILLION) 56

TABLE 27 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR REINFORCEMENT LEARNING, BY COUNTRY, 2017–2024 (USD MILLION) 56

TABLE 28 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR REINFORCEMENT LEARNING, BY COUNTRY, 2017–2024 (USD MILLION) 57

TABLE 29 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR REINFORCEMENT LEARNING, BY COUNTRY, 2017–2024 (USD MILLION) 57

TABLE 30 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR UNSUPERVISED LEARNING, BY REGION, 2017–2024 (USD MILLION) 58

TABLE 31 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR UNSUPERVISED LEARNING, BY COUNTRY, 2017–2024 (USD MILLION) 58

TABLE 32 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR UNSUPERVISED LEARNING, BY COUNTRY, 2017–2024 (USD MILLION) 58

TABLE 33 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR UNSUPERVISED LEARNING, BY COUNTRY, 2017–2024 (USD MILLION) 59

TABLE 34 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER MACHINE LEARNING TECHNOLOGIES, BY REGION, 2017–2024 (USD MILLION) 59

TABLE 35 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET

FOR OTHER MACHINE LEARNING TECHNOLOGIES, BY COUNTRY,

2017–2024 (USD MILLION) 60

TABLE 36 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER MACHINE LEARNING TECHNOLOGIES, BY COUNTRY, 2017–2024 (USD MILLION) 60

TABLE 37 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER MACHINE LEARNING TECHNOLOGIES, BY COUNTRY, 2017–2024 (USD MILLION) 60

TABLE 38 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2017–2024 (USD MILLION) 61

TABLE 39 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET

FOR OTHER TECHNOLOGIES, BY COUNTRY, 2017–2024 (USD MILLION) 61

TABLE 40 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2017–2024 (USD MILLION) 62

TABLE 41 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2017–2024 (USD MILLION) 62

TABLE 42 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION,

2017–2024 (USD MILLION) 64

TABLE 43 INDICATIVE LIST OF INITIATIVES IN IMMUNO-ONCOLOGY DRUG DEVELOPMENT 65

TABLE 44 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR IMMUNO-ONCOLOGY, BY REGION, 2017–2024 (USD MILLION) 65

TABLE 45 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR IMMUNO-ONCOLOGY, BY COUNTRY, 2017–2024 (USD MILLION) 65

TABLE 46 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR

IMMUNO-ONCOLOGY, BY COUNTRY, 2017–2024 (USD MILLION) 66

TABLE 47 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR

IMMUNO-ONCOLOGY, BY COUNTRY, 2017–2024 (USD MILLION) 66

TABLE 48 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR NEURODEGENERATIVE DISEASES, BY REGION, 2017–2024 (USD MILLION) 67

TABLE 49 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR NEURODEGENERATIVE DISEASES, BY COUNTRY, 2017–2024 (USD MILLION) 67

TABLE 50 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR NEURODEGENERATIVE DISEASES, BY COUNTRY, 2017–2024 (USD MILLION) 68

TABLE 51 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR NEURODEGENERATIVE DISEASES, BY COUNTRY, 2017–2024 (USD MILLION) 68

TABLE 52 INDICATIVE LIST OF DEVELOPMENTS IN CARDIOVASCULAR DRUG DEVELOPMENT 69

TABLE 53 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2017–2024 (USD MILLION) 69

TABLE 54 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2017–2024 (USD MILLION) 69

TABLE 55 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2017–2024 (USD MILLION) 70

TABLE 56 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2017–2024 (USD MILLION) 70

TABLE 57 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR METABOLIC DISEASES, BY REGION, 2017–2024 (USD MILLION) 71

TABLE 58 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2017–2024 (USD MILLION) 71

TABLE 59 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2017–2024 (USD MILLION) 71

TABLE 60 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2017–2024 (USD MILLION) 72

TABLE 61 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER APPLICATIONS, BY REGION, 2017–2024 (USD MILLION) 72

TABLE 62 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2017–2024 (USD MILLION) 73

TABLE 63 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2017–2024 (USD MILLION) 73

TABLE 64 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2017–2024 (USD MILLION) 73

TABLE 65 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER,

2017–2024 (USD MILLION) 75

TABLE 66 INDICATIVE LIST OF DEVELOPMENTS 76

TABLE 67 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2017–2024 (USD MILLION) 76

TABLE 68 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,

2017–2024 (USD MILLION) 77

TABLE 69 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,

2017–2024 (USD MILLION) 77

TABLE 70 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,

2017–2024 (USD MILLION) 77

TABLE 71 INDICATIVE LIST OF COLLABORATIONS WITH CROS 78

TABLE 72 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2017–2024 (USD MILLION) 78

TABLE 73 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2017–2024 (USD MILLION) 79

TABLE 74 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2017–2024 (USD MILLION) 79

TABLE 75 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2017–2024 (USD MILLION) 79

TABLE 76 INDICATIVE LIST OF RESEARCH COLLABORATIONS 80

TABLE 77 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR RESEARCH

CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES, BY REGION,

2017–2024 (USD MILLION) 80

TABLE 78 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET

FOR RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES,

2017–2024 (USD MILLION) 81

TABLE 79 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR

RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES,

2017–2024 (USD MILLION) 81

TABLE 80 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR

RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES,

2017–2024 (USD MILLION) 81

TABLE 81 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY REGION,

2017–2024 (USD MILLION) 83

TABLE 82 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,

BY COUNTRY, 2017–2024 (USD MILLION) 85

TABLE 83 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,

BY OFFERING, 2017–2024 (USD MILLION) 85

TABLE 84 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,

BY TECHNOLOGY, 2017–2024 (USD MILLION) 85

TABLE 85 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,

BY APPLICATION, 2017–2024 (USD MILLION) 86

TABLE 86 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,

BY END USER, 2017–2024 (USD MILLION) 86

TABLE 87 INDICATIVE LIST OF STRATEGIC DEVELOPMENTS 87

TABLE 88 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2017–2024 (USD MILLION) 87

TABLE 89 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION) 88

TABLE 90 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2017–2024 (USD MILLION) 88

TABLE 91 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2017–2024 (USD MILLION) 88

TABLE 92 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2017–2024 (USD MILLION) 89

TABLE 93 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,

BY TECHNOLOGY, 2017–2024 (USD MILLION) 90

TABLE 94 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,

BY APPLICATION, 2017–2024 (USD MILLION) 90

TABLE 95 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2017–2024 (USD MILLION) 90

TABLE 96 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2017–2024 (USD MILLION) 91

TABLE 97 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,

BY TECHNOLOGY, 2017–2024 (USD MILLION) 91

TABLE 98 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,

BY APPLICATION, 2017–2024 (USD MILLION) 92

TABLE 99 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,

BY END USER, 2017–2024 (USD MILLION) 92

TABLE 100 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,

BY COUNTRY, 2017–2024 (USD MILLION) 94

TABLE 101 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,

BY OFFERING, 2017–2024 (USD MILLION) 94

TABLE 102 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,

BY TECHNOLOGY, 2017–2024 (USD MILLION) 94

TABLE 103 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,

BY APPLICATION, 2017–2024 (USD MILLION) 95

TABLE 104 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,

BY END USER, 2017–2024 (USD MILLION) 95

TABLE 105 INDICATIVE LIST OF STRATEGIC DEVELOPMENTS 96

TABLE 106 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2017–2024 (USD MILLION) 96

TABLE 107 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION) 97

TABLE 108 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2017–2024 (USD MILLION) 97

TABLE 109 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2017–2024 (USD MILLION) 97

TABLE 110 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,

BY OFFERING, 2017–2024 (USD MILLION) 98

TABLE 111 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,

BY TECHNOLOGY, 2017–2024 (USD MILLION) 98

TABLE 112 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,

BY APPLICATION, 2017–2024 (USD MILLION) 99

TABLE 113 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,

BY END USER, 2017–2024 (USD MILLION) 99

TABLE 114 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,

BY OFFERING, 2017–2024 (USD MILLION) 100

TABLE 115 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,

BY TECHNOLOGY, 2017–2024 (USD MILLION) 100

TABLE 116 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,

BY APPLICATION, 2017–2024 (USD MILLION) 100

TABLE 117 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2017–2024 (USD MILLION) 101

TABLE 118 ROE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2017–2024 (USD MILLION) 101

TABLE 119 ROE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION) 102

TABLE 120 ROE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2017–2024 (USD MILLION) 102

TABLE 121 ROE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2017–2024 (USD MILLION) 102

TABLE 122 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY COUNTRY, 2017–2024 (USD MILLION) 103

TABLE 123 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2017–2024 (USD MILLION) 103

TABLE 124 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION) 104

TABLE 125 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2017–2024 (USD MILLION) 104

TABLE 126 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2017–2024 (USD MILLION) 104

TABLE 127 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2017–2024 (USD MILLION) 105

TABLE 128 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION) 105

TABLE 129 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2017–2024 (USD MILLION) 106

TABLE 130 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2017–2024 (USD MILLION) 106

TABLE 131 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2017–2024 (USD MILLION) 107

TABLE 132 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION) 107

TABLE 133 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2017–2024 (USD MILLION) 108

TABLE 134 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2017–2024 (USD MILLION) 108

TABLE 135 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2017–2024 (USD MILLION) 109

TABLE 136 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION) 109

TABLE 137 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2017–2024 (USD MILLION) 109

TABLE 138 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2017–2024 (USD MILLION) 110

TABLE 139 ROAPAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2017–2024 (USD MILLION) 110

TABLE 140 ROAPAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,

BY TECHNOLOGY, 2017–2024 (USD MILLION) 111

TABLE 141 ROAPAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,

BY APPLICATION, 2017–2024 (USD MILLION) 111

TABLE 142 ROAPAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2017–2024 (USD MILLION) 111

TABLE 143 ROW: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2017–2024 (USD MILLION) 112

TABLE 144 ROW: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION) 112

TABLE 145 ROW: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2017–2024 (USD MILLION) 113

TABLE 146 ROW: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2017–2024 (USD MILLION) 113

TABLE 147 PRODUCT LAUNCHES AND ENHANCEMENTS, 2016–2019 119

TABLE 148 EXPANSIONS, 2016–2019 119

TABLE 149 ACQUISITIONS, 2016–2019 120

TABLE 150 OTHER STRATEGIES, 2016–2019 120

List Of Figures, Charts and Diagrams
in Artificial Intelligence (AI) in Drug Discovery Market by Component (Software, Service), Technology (ML, DL), Application (Neurodegenerative Diseases, Immuno-Oncology, CVD), End User (Pharmaceutical & Biotechnology, CRO), Region - Global forecast to 2024 [Published by MarketsandMarkets]

LIST OF FIGURES


FIGURE 1 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY: MARKET SEGMENTATION 18

FIGURE 2 RESEARCH DESIGN 21

FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS 25

FIGURE 4 BOTTOM-UP APPROACH 27

FIGURE 5 TOP-DOWN APPROACH 27

FIGURE 6 DATA TRIANGULATION METHODOLOGY 28

FIGURE 7 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING,

2019 VS. 2024 (USD MILLION) 30

FIGURE 8 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2019–2024 31

FIGURE 9 ARTIFICIAL LEARNING IN DRUG DISCOVERY MARKET, BY APPLICATION,

2019 VS. 2024 (USD MILLION) 32

FIGURE 10 ARTIFICIAL LEARNING IN DRUG DISCOVERY MARKET, BY END USER,

2019 VS. 2024 (USD MILLION) 33

FIGURE 11 GEOGRAPHICAL SNAPSHOT OF THE ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET 34

FIGURE 12 NEED TO CONTROL DRUG DISCOVERY & DEVELOPMENT COSTS IS A MAJOR FACTOR DRIVING THE ADOPTION OF AI IN DRUG DISCOVERY SOLUTIONS 35

FIGURE 13 SERVICES SEGMENT TO WITNESS THE HIGHEST GROWTH DURING

THE FORECAST PERIOD 36

FIGURE 14 DEEP LEARNING SEGMENT ACCOUNTED FOR THE LARGEST MARKET SHARE

IN 2018 37

FIGURE 15 NORTH AMERICA IS THE FASTEST-GROWING REGIONAL MARKET FOR AI

IN DRUG DISCOVERY 38

FIGURE 16 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: DRIVERS, OPPORTUNITIES, AND CHALLENGES 39

FIGURE 17 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY

MARKET SNAPSHOT 84

FIGURE 18 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SNAPSHOT 93

FIGURE 19 KEY PLAYERS ADOPTED ORGANIC AS WELL AS INORGANIC GROWTH STRATEGIES 114

FIGURE 20 MARKET EVOLUTION FRAMEWORK 115

FIGURE 21 AI IN DRUG DISCOVERY MARKET SHARE ANALYSIS, BY KEY PLAYER, 2018 116

FIGURE 22 COMPETITIVE LEADERSHIP MAPPING OF THE AI IN DRUG DISCOVERY MARKET 118

FIGURE 23 MICROSOFT CORPORATION: COMPANY SNAPSHOT 121

FIGURE 24 NVIDIA CORPORATION: COMPANY SNAPSHOT 123

FIGURE 25 IBM CORPORATION: COMPANY SNAPSHOT 125

FIGURE 26 ALPHABET: COMPANY SNAPSHOT 127

Additional Details

Publisher

MarketsandMarkets

Publisher Information

Reference

237298 | HIT 7445

Number of Pages

156

Report Format

PDF

MarketsandMarkets Reports

Related Reports

TitleDate PublishedPrice fromMore Details
SAVE 15% today! Sugar-Based Excipients Market by Product (Actual Sugars, Sugar Alcohols, Artificial Sweeteners), Type (Powder/Granule, Crystal, Syrup), Functionality (Filler & Diluent, Tonicity Agents), Formulation (Oral, Topical, Parenteral) - Global Forecast to 2021
The global sugar excipients market is estimated to grow at a CAGR of 4.3% from 2016 to 2021, to reac...
08 Dec 2016 by MarketsandMarkets USD $4,803 (normally
USD $5,651)
More Info
SAVE 15% today! Total Artificial Heart - Medical Devices Pipeline Assessment, 2016
Total Artificial Heart - Medical Devices Pipeline Assessment, 2016SummaryGlobalData's Medical Device...
01 Jun 2016 by Global Data USD $2,125 (normally
USD $2,500)
More Info
SAVE 15% today! Total Artificial Heart - Medical Devices Pipeline Assessment, 2016
Total Artificial Heart - Medical Devices Pipeline Assessment, 2016SummaryGlobalData's Medical Device...
01 Jun 2016 by Global Data USD $2,125 (normally
USD $2,500)
More Info
SAVE 15% today! Artificial Disc Replacement Systems - Medical Devices Pipeline Assessment, 2016
Artificial Disc Replacement Systems - Medical Devices Pipeline Assessment, 2016SummaryGlobalData's M...
11 Mar 2016 by Global Data USD $3,400 (normally
USD $4,000)
More Info
SAVE 15% today! Artificial Pancreas - Medical Devices Pipeline Assessment, 2016
Artificial Pancreas - Medical Devices Pipeline Assessment, 2016SummaryGlobalData's Medical Devices s...
11 Mar 2016 by Global Data USD $3,400 (normally
USD $4,000)
More Info
SAVE 15% today! North America Unsaturated Polyester Resin Market By Type, By Application (Building & Construction, Marine, Automotive & Transportation, Pipes & Tanks, Electrical & Electronics, Wind Energy, Artificial Stones), By Geography– Analysis & Forecast to 2020
Unsaturated polyester resins (UPR) are highly durable, when they are cross linked with monomers such...
01 Oct 2015 by MicroMarketMonitor USD $2,253 (normally
USD $2,651)
More Info
SAVE 15% today! Middle East Well Intervention Market by Service Type (Logging & Bottom Hole Survey, Tubing/Packer Failure & Repair, Stimulation, Artificial Lift, Others), Application (Onshore & Offshore), & Country - Analysis & Forecast to 2019
Well intervention services are required throughout the lifespan of an oil & gas well. Worldwide incr...
13 May 2015 by MarketsandMarkets USD $2,253 (normally
USD $2,651)
More Info
SAVE 15% today! Asia Pacific Well Intervention Market by Service Type (Logging & Bottom Hole Survey, Tubing/Packer Failure & Repair, Stimulation, Artificial Lift, Others), by Application (Onshore & Offshore), and by Country - Analysis & Forecast To 2019
Asia-Pacific well intervention services market is estimated to grow at a CAGR of 3.5% from 2014 to 2...
07 May 2015 by MarketsandMarkets USD $2,253 (normally
USD $2,651)
More Info
SAVE 15% today! North America Well Intervention Market by Service Types (Logging & Bottom Hole Survey, Tubing/Packer Failure & Repair, Stimulation, Artificial Lift, Others), By Application (Onshore & Offshore), and By Countries – Analysis & Forecast to 2019
The North America well intervention market constitutes 50% of the global Well Intervention market, a...
02 May 2015 by MarketsandMarkets USD $2,253 (normally
USD $2,651)
More Info
SAVE 15% today! Africa Well Intervention Service Market by Types (Logging & Bottom Hole Survey, Tubing/Packer Failure & Repair, Stimulation, Artificial Lift, Others), by Application (Onshore & Offshore), and by Countries - Analysis and Forecast to 2019
The well intervention services market is estimated to grow at a CAGR of 4% from 2014 to 2019. Geogra...
28 Apr 2015 by MarketsandMarkets USD $2,253 (normally
USD $2,651)
More Info

This report is published by MarketsandMarkets

Download Free Report Summary PDF

Artificial Intelligence (AI) in Drug Discovery Market by Component (Software, Service), Technology (ML, DL), Application (Neurodegenerative Diseases, Immuno-Oncology, CVD), End User (Pharmaceutical & Biotechnology, CRO), Region - Global forecast to 2024 [Published by MarketsandMarkets] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...